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Abstract
Introduction: Renal artery stenosis (RAS) is not 
rare, but is often asymptomatic. In older individuals, 
atherosclerosis is the most common cause of RAS. 
Atherosclerotic RAS is usually one manifestation of wide 
spread atherosclerotic disease, and its presence increases 
the morbidity and mortality of other manifestations of 
atherosclerotic disease.
Review: Renal arterial disease discovered incidentally 
can be managed expectantly as long as blood pressure and 
kidney function are well maintained. Revascularization 
can be considered with the prospect of improving blood 
pressure control or impaired kidney function, but its 
outcomes are heterogeneous. The potential for serious 
deterioration in kidney function after revascularization 
underscores the need to select patients carefully for 
vascular procedures in the kidney. 
Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) are effective in 
treating most cases of hypertension in atherosclerotic 
RAS. In addition, clinical data suggest that the survival 
of patients with renovascular hypertension is better 
when ACE inhibitors are part of therapy than when 
they are not. This benefit may be in part due to the fact 
that ACE inhibitors reduce morbidity and mortality in 
congestive heart failure which is common co-morbidity 
in patients with RAS. Withdrawal of the ACE inhibitor in 
such patients should occur only when the rise in serum 
creatinine level exceeds 30% above baseline within 
the first  two months of ACE inhibitor initiation, or if 
hyperkalemia develops. 
Conclusion: Renovascular hypertension is best managed 
with ACE inhibitors or ARBs as long as blood pressure 
and renal function are well maintained. Revascularization 
should be considered if blood pressure control is not 
adequate or if renal function deteriorates.
Key words: renovascular disease, renal artery stenosis, 
renal artery occlusion 
Introduction
Renal vascular disease manifesting as renal artery 
stenosis (RAS) is not a rare entity, but is quite often 
asymptomatic. Among 716 potential living kidney 
donors who underwent conventional arteriography in 
a single center, 6.6% had renovascular disease due to 
fibromuscular dysplasia and 1.7% had renovascular 
disease due to atherosclerosis [1].
Atherosclerosis is by far the most common cause of 
RAS in older individuals. Population based studies have 
shown that hemodynamically significant RAS affects up 
to 6.8% of individuals above 65 years of age and that 
its presence is significantly and independently associated 
with increasing age, low high-density lipoprotein 
cholesterol levels and increasing systolic blood pressure 
[2].  RAS is also reported to affect 1-5% of all patients 
with hypertension [3], and this percentage increases to 
17% in case of coexistent diabetes mellitus [4].
Atherosclerotic RAS rarely occurs in isolation, but is 
usually one manifestation of wide spread atherosclerotic 
disease. This is reflected by the fact that up to 26% of 
patients referred for evaluation of peripheral vascular 
disease [5], 10.4% of autopsy patients with stroke [6] and 
4.8-15% of patients undergoing abdominal aortography 
immediately following coronary angiography [7, 8] have 
significant RAS.
The complex interaction between atherosclerotic RAS 
and hypertension is further enhanced by the deleterious 
effect of RAS on renal perfusion and kidney function. This 
may explain, at least in part, the negative impact of RAS 
on the morbidity and mortality of other manifestations of 
atherosclerotic disease.
In a retrospective analysis of patients with hypertension 
and renovascular disease, their 5 and 10 year survival 
rates were found to be 83% and 67% respectively, which 
was greatly reduced in comparison with that of matched 
controls in the general population, and was also less than 
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that of matched hypertensive patients. Age, cigarette 
smoking and the presence of atheromatous disease were 
significantly and independently related to outcome 
among these patients [9].
The prospective Cardiovascular Health Study has also 
shown that the presence of renovascular disease conferred 
an increased risk of adverse coronary events, which was 
not dependent on the effects of associated atherosclerotic 
risk factors, other prevalent cardiovascular disease, or 
high blood pressure [10].
In another cohort of patients who underwent abdominal 
aortography immediately following coronary angio-
graphy, the presence of significant RAS was found to 
be a strong independent predictor of mortality, with an 
unadjusted 4-year survival rate of 57% compared to 89% 
in patients without RAS. In addition, bilateral disease was 
associated with a 4-year survival rate of 47%, compared 
to 59% in patients with unilateral disease [7].
Also, in a large cohort of patients who underwent intra-
arterial digital subtraction angiography for peripheral 
vascular disease (PVD) in a single center, RAS was an 
independent  predictor of mortality. The estimated 5-year 
survival probability was 37% for patients with RAS as 
compared with 72% for patients without RAS [5].
Regarding end stage renal disease (ESRD) patients, 
renovascular disease was characterized clinically  in 83 
of 683 dialysis patients in a single center. Their 2-year, 
5-year and 10-year survival rates were 56%, 18%, and 
5% respectively, which was significantly worse than 
other diagnostic groups [11].
Review 
Atherosclerotic RAS is progressive in nature. However, 
the rate of progression is quite variable, and this can have 
a great impact on management decisions.
In a prospective study among a group of hypertensive 
patients that used duplex scanning to document the natural 
history of atherosclerotic RAS, the 2-year cumulative 
incidence of renal atrophy (a reduction in kidney length 
of greater than 1 cm) was 5.5%, 11.7%, and 20.8% in 
kidneys with a baseline renal artery disease classification 
of normal, less than 60% stenosis, and 60% or more 
stenosis respectively. Also, there was a significant risk of 
renal atrophy among kidneys exposed to elevated systolic 
blood pressure and among those with low renal cortical 
blood flow velocity as assessed by renal duplex scanning. 
The occurrence of renal atrophy was well correlated 
with changes in the serum creatinine concentration [12]. 
Also, in the DRASTIC trial, 9% of patients who were 
randomized to receive medical treatment experienced 
total occlusion of the affected renal artery by 12 months 
[13].
However, in a prospective population-based study that 
estimated the incidence of new RAS and  the progression 
of established RAS among elderly Americans with a low 
rate of clinical hypertension who were followed up for 
8 years, progression to significant RAS was observed in 
only 4% of kidneys, and no case of RAS diagnosed at 
baseline progressed to occlusion [14].
This demonstrates that renal arterial disease discovered 
incidentally can pose no problem for either kidney 
function or blood pressure for several years, and as 
long as blood pressure and kidney function are well 
maintained, expectant management appears to be entirely 
appropriate. 
Nevertheless, revascularization of RAS is often 
considered with the prospect of improving blood 
pressure control or impaired kidney function. The 
potential of revascularization to prevent or delay further 
decline in kidney function in some patients with RAS 
was documented by a number of observational studies. 
Impressive early results in this respect were reported by 
Morris and colleagues, who noted that  renal function 
recovered in eight patients who underwent surgical 
revascularization at a time before the general availability 
of dialysis, six of whom returned to essentially normal 
renal function [15].
Surprisingly, randomized controlled trials comparing 
percutaneous transluminal renal angioplasty (PTRA) 
with medical therapy in the treatment of RAS failed to 
demonstrate any long term benefit on the preservation 
of renal function in the PTRA group, even though 
angioplasty was slightly more effective in improving 
blood pressure control in some studies. Overall, the 
evidence from these studies was not sufficiently robust to 
determine the comparative effectiveness of angioplasty 
and medical treatment in the management of RAS [16, 
17].
The failure of these studies to detect a meaningful overall 
improvement in serum creatinine level may be explained 
by the heterogeneous outcomes of revascularization. 
Overall, among RAS patients who underwent PTRA 
with stenting, 26% had an improvement in glomerular 
filtration rate (GFR), 48% had a stable GFR, whereas 
26% had a decline in GFR [18].
The rapid deterioration in renal function that occurs in 
some patients after revascularization may be due to the 
relatively high risk of complications of revascularization. 
Apart from contrast nephropathy, possible complications 
of PTRA include hemorrhage, injury to the femoral, iliac 
or renal arteries, stent thrombosis, distal renal embolism, 
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septicemia, and cholesterol embolism to the lower limbs 
[18].
As expected, the risk is even higher for surgical 
revascularization. In a retrospective analysis that compared 
surgical revascularization and PTRA in the management 
of RAS, both procedures had similar efficacy; however, 
surgical revascularization had a higher complication rate 
and higher thirty-day mortality than PTRA (9% versus 
2%) [19].
The potential for serious deterioration in kidney function 
after revascularization, percutaneous or surgical, and the 
possibility of serious complications underscore the need 
to select patients carefully for vascular procedures in the 
kidney. 
Several factors were explored for the potential of 
predicting which patient is most likely to benefit 
from revascularization. A shrunken kidney, a kidney 
with cortical necrosis or a kidney proven by biopsy to 
have irreversible damage is not likely to benefit from 
revascularization. In addition, a duplex ultrasound 
scan revealing renal resistance index greater than 80 
indicates small vessel and large vessel disease. Such 
findings predict poor response to either percutaneous or 
surgical revascularization with respect to improvement in 
hypertension, renal function, or kidney survival [20].
In a secondary analysis of the DRASTIC study, only 
patients with bilateral RAS had a substantial benefit on 
creatinine clearance, and they also seemed to benefit 
most with regard to blood pressure control [21].
In a study of 105 patients with hemodynamically 
significant atherosclerotic RAS who underwent PTRA 
with stenting, it was found that the subgroup of patients 
which initially had a moderately or severely impaired GFR 
had a significant increase in the calculated GFR one year 
after the procedure despite no significant change in blood 
pressure. In contrast, the subgroup which had normal 
or mildly impaired GFR,  had significant reductions in 
systolic and diastolic blood pressure, but no significant 
change in the calculated GFR [22].
Among 59 chronic renal failure patients who underwent 
PTRA for hemodynamically significant RAS, it was found 
that a rapidly progressive decline in renal function prior 
to the procedure was associated with a more favorable 
response to PTRA regarding renal failure progression 
[23].
Timing of revascularization is also of paramount 
importance. In a cohort of 241 patients who were treated 
with PTRA and stent implantation for significant RAS, 
the long term survival was found to depend largely on 
renal function and left ventricular function at the time of 
the procedure; the 5-year survival rates for patients with 
baseline serum creatinine of more than 2.5 mg/dl, 1.2-2.5 
mg/dl and less than 1.2 mg/dl were 29.6%, 89.1%, 
and 95.4% respectively [24]. Hence, revascularization 
should not be delayed for a suitable candidate in order 
to spare him/her the development of advanced ischemic 
nephropathy or congestive heart failure.
The American College of Cardiology and the American 
Heart Association have recently published guidelines 
for the management of patients with peripheral arterial 
disease, including RAS [25]. According to these 
guidelines, percutaneous revascularization is indicated 
for patients with hemodynamically significant unilateral 
or bilateral RAS and accelerated hypertension, resistant 
hypertension, malignant hypertension, hypertension with 
an unexplained unilateral small kidney, hypertension 
with intolerance to medication, recurrent unexplained 
congestive heart failure or sudden unexplained pulmonary 
edema, or unstable angina. It is also indicated for patients 
with bilateral RAS or RAS to a solitary functioning kidney 
and progressive chronic kidney disease, and may be 
considered for patients with unilateral RAS and chronic 
renal insufficiency. Vascular surgical reconstruction 
is indicated for patients with RAS who have a clinical 
indication for revascularization when percutaneous 
revascularization is not feasible or has been unsuccessful 
[25].
Angiotensin converting enzyme (ACE) inhibitors and 
angiotensin receptor blockers (ARBs) are effective 
in treating 86 – 92% of cases of hypertension and 
atherosclerotic RAS [26]. As a result of the wider use of 
these agents for the treatment of hypertension, it is likely 
that many individuals with renovascular hypertension are 
never detected but are simply treated.
In addition, clinical data suggest that the survival of 
patients with renovascular hypertension is better when 
ACE inhibitors are part of therapy than when they are not 
[27]. This benefit may be in part due to the fact that ACE 
inhibitors reduce morbidity and mortality in congestive 
heart failure [28], which is common co-morbidity in 
patients with RAS.
However, a major concern regarding the use of ACE 
inhibitors for renovascular hypertension is their potential 
to cause functional acute renal failure. A rise in serum 
creatinine of up to 30% above baseline following 
the initiation of ACE inhibitors in patients with heart 
failure is a normal hemodynamic response, and a strong 
association exists between this acute increase in serum 
creatinine and long term preservation of renal function; 
withdrawal of the ACE inhibitor in such patients should 
occur only when the rise in serum creatinine level exceeds 
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30% above baseline within the first 2 months of ACE 
inhibitor initiation, or hyperkalemia develops [29].
The benefits of revascularization for such patient are not 
limited to restoration of kidney function and improved 
blood pressure control, but extend to an improvement in 
heart failure symptoms [40]. Renal revascularization also 
has the potential to ameliorate the increased risk of adverse 
coronary events which is associated with renovascular 
disease [9]. This issue will be addressed by a prospective 
trial, Cardiovascular Outcomes in Renal Artery Lesions 
(CORAL), which will examine the effect of intensive 
medical management versus revascularization with or 
without stenting on cardiovascular events in patients with 
RAS [41].
Conclusion
Renal arterial disease discovered incidentally can be 
managed expectantly as long as blood pressure and 
kidney function are well maintained. Renovascular 
hypertension is best managed with ACE inhibitors or 
ARBs. Revascularization can be considered for a select 
group of patients with the prospect of improving blood 
pressure control or impaired kidney function. 
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